Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ETHZ NYSE:IBIO OTCMKTS:ICOTF NYSEAMERICAN:SYN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeETHZFlag Ship Acquisition$2.44$0.00$0.66▼$17.75$14.74M0.3730.45 million shs11.65 million shsIBIOiBio$0.83-2.6%$0.74$0.56▼$6.89$16.37M0.861.50 million shs347,220 shsICOTFiCo Therapeutics$0.47-0.4%$0.37$0.80▼$1.82$4.28M2.034,760 shs102,585 shsSYNSynthetic Biologics$0.00$0.97▼$4.56$16.16M1.38197,338 shs57,700 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceETHZFlag Ship Acquisition+5.63%-13.17%+243,999,900.00%+243,999,900.00%+243,999,900.00%IBIOiBio+2.37%+4.54%+43.86%-10.02%-51.98%ICOTFiCo Therapeutics0.00%+9.08%+4.08%+16.13%+28.24%SYNSynthetic Biologics0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeETHZFlag Ship Acquisition$2.44$0.00$0.66▼$17.75$14.74M0.3730.45 million shs11.65 million shsIBIOiBio$0.83-2.6%$0.74$0.56▼$6.89$16.37M0.861.50 million shs347,220 shsICOTFiCo Therapeutics$0.47-0.4%$0.37$0.80▼$1.82$4.28M2.034,760 shs102,585 shsSYNSynthetic Biologics$0.00$0.97▼$4.56$16.16M1.38197,338 shs57,700 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceETHZFlag Ship Acquisition+5.63%-13.17%+243,999,900.00%+243,999,900.00%+243,999,900.00%IBIOiBio+2.37%+4.54%+43.86%-10.02%-51.98%ICOTFiCo Therapeutics0.00%+9.08%+4.08%+16.13%+28.24%SYNSynthetic Biologics0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceETHZFlag Ship Acquisition 0.00N/AN/AN/AIBIOiBio 3.00Buy$5.00500.38% UpsideICOTFiCo Therapeutics 0.00N/AN/AN/ASYNSynthetic Biologics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ICOTF, IBIO, SYN, and ETHZ Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/25/2025IBIOiBioChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.00(Data available from 9/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookETHZFlag Ship AcquisitionN/AN/AN/AN/A$2.91 per shareN/AIBIOiBio$375K43.65N/AN/A$1.41 per share0.59ICOTFiCo TherapeuticsN/AN/AN/AN/A($0.07) per shareN/ASYNSynthetic BiologicsN/AN/AN/AN/A$4.95 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateETHZFlag Ship Acquisition-$6.17M-$15.070.00∞N/AN/A-141.25%-80.77%N/AIBIOiBio-$24.91M-$1.74N/AN/AN/AN/A-73.15%-45.51%N/AICOTFiCo Therapeutics-$1.11M-$0.40N/A∞N/AN/AN/A-288.85%N/ASYNSynthetic Biologics-$14.27M-$1.21N/AN/AN/AN/A-26.14%-22.74%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthETHZFlag Ship AcquisitionN/AN/AN/AN/AN/AIBIOiBioN/AN/AN/AN/AN/AICOTFiCo TherapeuticsN/AN/AN/AN/AN/ASYNSynthetic BiologicsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioETHZFlag Ship AcquisitionN/A0.580.58IBIOiBio0.051.761.76ICOTFiCo TherapeuticsN/A0.720.72SYNSynthetic BiologicsN/A4.144.14Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipETHZFlag Ship Acquisition4.07%IBIOiBio7.90%ICOTFiCo TherapeuticsN/ASYNSynthetic Biologics74.38%Insider OwnershipCompanyInsider OwnershipETHZFlag Ship Acquisition38.20%IBIOiBio0.58%ICOTFiCo TherapeuticsN/ASYNSynthetic Biologics2.15%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableETHZFlag Ship Acquisition76.04 million3.73 millionN/AIBIOiBio10019.66 million9.82 millionN/AICOTFiCo TherapeuticsN/A9.05 millionN/ANot OptionableSYNSynthetic Biologics1615.84 million15.50 millionNot OptionableICOTF, IBIO, SYN, and ETHZ HeadlinesRecent News About These CompaniesFrom Synthetic Identities to Synthetic Receipts: The New Frontier of FraudJuly 17, 2025 | securityinfowatch.comSSynthetic Natural Gas Could Provide Lower-Cost EnergyJuly 17, 2025 | independentnews.comISynthetic Darwin and Star26 Capital Partner to Advance Defense AIJuly 16, 2025 | tmcnet.comThe Hidden Downside Of Synthetic Stone CountertopsJuly 16, 2025 | msn.comPakenham Synthetic Monday tips: Laying a $2.30FJuly 15, 2025 | punters.com.auPBallarat Synthetic Tuesday tips: $11 value betJuly 15, 2025 | punters.com.auPMost Major Ice Cream Brands Will Remove Synthetic Dyes by 2028July 15, 2025 | usnews.comSarcoidosis: Infliximab Has Some Effect, Other Third-Line Therapies Show PromiseJuly 11, 2025 | pulmonologyadvisor.comPSynthetic Dyes Present in 19% of US Food ProductsJuly 9, 2025 | empr.comEBallarat Synthetic preview and tips: $11 value betJuly 9, 2025 | punters.com.auPSynthetic Dyes Present in 19 Percent of U.S. Food ProductsJuly 4, 2025 | msn.comFlexiteek Expands Synthetic Decking Line with New Tritone FinishJuly 3, 2025 | msn.comControversial ‘Synthetic Human Genome Project’ Spurs Debate Over Ethics of Building Human DNA from ScratchJuly 2, 2025 | thedebrief.orgTOn The Punt: Gilbert Gardiner's tips for Ballarat Synthetic on TuesdayJuly 2, 2025 | punters.com.auPSynthetic data, real results: Rewiring industrial inspection to work with AIJuly 1, 2025 | imveurope.comIUK launches bold Synthetic Human Genome Project: Can human DNA be built from scratch?June 27, 2025 | indiatvnews.comIAstroTurf Secures Historic Partnership as Official Synthetic Turf of Major League BaseballJune 27, 2025 | sfexaminer.comSSynthetic DNA research could lead to the creation of artificial life, Irish professor saysJune 27, 2025 | independent.ieIWhich mesh is best? Outcomes for abdominal ventral hernia repair patients projected by new research modelJune 25, 2025 | medicaldialogues.inMEULAR Updates Recommendations for Managing Rheumatoid ArthritisJune 20, 2025 | medscape.comMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeICOTF, IBIO, SYN, and ETHZ Company DescriptionsFlag Ship Acquisition NASDAQ:ETHZ$2.44 0.00 (0.00%) As of 04:00 PM Eastern1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.iBio NYSE:IBIO$0.83 -0.02 (-2.57%) Closing price 04:00 PM EasternExtended Trading$0.84 +0.00 (+0.50%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.iCo Therapeutics OTCMKTS:ICOTFSatellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX™ and Leveraging MyoReGenX™, which identify stem cell based regeneration deficits in muscle diseases and develop therapeutic solutions. The company was founded by Frank Gleeson and Michael Rudnicki in 2018 and is headquartered in Toronto, Canada.Synthetic Biologics NYSEAMERICAN:SYNSynthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11 to treat cancer. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Synthetic Biologics, Inc. is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Should You Buy Figma Stock After Its 55% Post-IPO Drop? Ulta Beauty Stock: Strong Growth, Short-Term Volatility Ahead Joby's Stock Is Quiet, But a Storm of Catalysts Is Brewing The Quiet Before the Catalyst: Vertical Aerospace's Next Move Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver Insiders Sell These High-Quality Stocks: Why Investors Shouldn’t Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
